NCT07470489
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Jan 31, 2027 to Oct 29, 2026
- Site details revised
- Notable Start date: Sep 30, 2026 to Jan 31, 2027
- Eligibility criteria expanded, about 69 words
- Study description expanded, about 11 words
- Minor Study title shortened, about 9 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year
Arms and interventions
Treatment with Zanzalintinib + CemiplimabExperimental
Participants will be treated in 21-day cycles with zanzalintinib 60 mg po daily from days 1-21 and cemiplimab 350 mg IV on day 1 of each cycle. Patients will be treated for a maximum of 24 cycles.
Drugs: Cemiplimab, Zanzalintinib
Sites
1 site in 1 country
- MD Anderson Cancer CenterHouston, Texas, United States